Bhavani Potluri

Heme/Onc fellow @NYUGSOM_HemeOnc | IM @waynestate | Osmania Medical College Alum 🇮🇳

[ASCO @ASCO]

More breaking news from #ASCO26 Plenary: Selpercatinib significantly improves EFS vs placebo in early-stage RET fusion–positive NSCLC, per new results from the phase 3 LIBRETTO-432 trial. #ASCODailyNews has more: https://t.co/ubA5VVkHSd
@christine_lovly @cityofhope

[Anirban Maitra @Aiims1742]

#ASCO26 will be busy for @Perlmutter_CC faculty and trainees with many presentations and posters throughout the next few days!
Full details below:
https://t.co/F997h1Qhsf
@nyugrossman @JohnPLeonardMD @JaniceM10 @DrMhidalgo @DrDaveWise @docbraunstein @salmanpunekar @samyamshon

[John P. Leonard, MD @JohnPLeonardMD]

Excited to get started at #ASCO26 with @Perlmutter_CC @nyulangone activities!

[Dr. Estela Rodriguez @Latinamd]

The #ASCO26 schedule I wished someone had given me when I was as a Hem-Onc fellow interested in thoracic oncology- attending my first @ASCO meeting

This is just a start — try to learn about a different cancer type and connect with at least 2 new people each day.

And don’t miss the poster sessions: one of the best places to network, find future collaborators, and even explore job opportunities. @hemoncmiami @hemoncfellows

[Anirban Maitra @Aiims1742]

Excited at the launch of the @Perlmutter_CC KRAS Excellence Initiative (KRAS-X), a multidisciplinary effort focused on advancing clinical trials & translational research to improve care for patients with KRAS-mutated cancers. More details below:
https://t.co/qGXqK2e3Oc

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

What a day! The FDA has now approved the combination of oral decitabine/venetoclax for newly diagnosed older/unfit #AMLsm patients based on the ASCERTAIN V trial which I had the pleasure to present in #ASCO2025 on behalf of the investigators.
It was unheard of to treat AML patients with just 2 oral pills, and to see several of our patients some of whom are in their 80s achieve long lasting remissions and be completely outpatient for more than 2 years is really gratifying, especially when you think the average survival of these patients a decade ago was less than few months.
There is nothing better in clinical research that knowing that the drugs you helped get approved will not only help your own patients but will also hopefully help thousands of other patients who you will never meet.

[Veli Bakalov, MD @HemeOncBuddy]

Launching https://t.co/XPqbIcgSFT today = 5 years of hard work!

A free, oncologist-curated heme/onc resource — built for the bedside, the boards, and everyone in between.

Every entry cross-checked against OpenEvidence
@EvidenceOpen = Zero errors flagged.

What's inside ↓

[Paolo Tarantino @PTarantinoMD]

#AgelessGems💎 Treatment for ER+/HER2- BC keeps evolving at supersonic speed. Yet, some treatment pillars remain unchanged — shaped by decades of research. This 2020 review by @DrHBurstein wonderfully summarizes our understanding of the disease. Must read. https://t.co/wJVg8nW2Xy

[Anirban Maitra @Aiims1742]

5 year survival rates for cancers by stage.
From @AmericanCancer Cancer Statistics 2026
https://t.co/cPUAW3FMch
"These interventions (reductions in smoking, earlier detection & improved treatment) have contributed to a milestone 70% 5-year survival rate for all cancers combined"

[LARVOL @Larvol]

Plan your 2026 conference schedule better with @Larvol.

Here is our list of the Top 25 Oncology Conferences worldwide. Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/ct6tMIQHii

#LARVOL #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates #OncologyConferences #OncologyInsights #GI26 #GU26 #ASCO26 #EHA26 #AACR26 #ESMO26 #SITC26 #ASH26 #SABCS26 #2026Events #MedicalConferences

The conferences: @ASCO | @ASH_hematology | @SABCSSanAntonio | @EHA_Hematology | @myESMO | @sitcancer | @IASLC | @SocietyofHemOnc | @AACR

[NEJM @NEJM]

New in the January 1, 2026, issue of NEJM:

Sacituzumab Tirumotecan in EGFR-TKI–Resistant NSCLC (OptiTROP-Lung04 phase 3 trial) https://t.co/wus5DakKNl

Osimertinib plus Chemotherapy in 𝘌𝘎𝘍𝘙-Mutated NSCLC (FLAURA2 phase 3 trial) https://t.co/WCGjC88e6y

Brain-Penetrant Enzyme Therapy for MPS II https://t.co/5XnS0ZRWuF

Talquetamab and Teclistamab for Extramedullary Myeloma (RedirecTT-1 phase 2 study) https://t.co/KX8DYXj5tK

Subscribe to NEJM for the latest medical research: https://t.co/QFe1he3roV

[Toni Choueiri, MD @DrChoueiri]

HIGHEST RANKED TRIALS for 2025

TOP 10 #cancerclinicaltrials in 2025 w/MOST Impact

1/ #DeLLphi304 @NEJM led by #Zeusofoncology @g_mountzios @HenryDunantGR : In relapsed SCLC post-platinum, BiTE DLL-3 Tarlatamab improved mOS vs. Chemo (13.6 vs 8.3 m, HR 0.60). PFS and in cancer-related dyspnea also improved.

https://t.co/dlIvlySUT9

[ASCO TECAG @ASCOTECAG]

📚Check this out! With fellow TECAG members and guidance from KOLs, we put together a list of papers published in 2025 that are most relevant to #fellows w 2–3 picks per subspecialty.
🙏Hope it is helpful. 🎉Happy New Year! 🎊🎈

#MedEd #Trainee #OncMedEdCop @ASCO

[Toni Choueiri, MD @DrChoueiri]

IT IS THIS TIME OF THE YEAR AGAIN!

TOP 10 GU clinical trials in 2025!

1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%.
@tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO

https://t.co/mbl2VKLZ2N

[Paolo Tarantino @PTarantinoMD]

When I moved to the US in 2021, breast oncology was very different. With 2025 coming to an end, I decided to look back and review 10 major milestones in BC medical oncology care we saw over the past 5 years. With hope and expectation to see so much more unfolding over the next 5!

[John P. Leonard, MD @JohnPLeonardMD]

This will be great for patients!
All updates you need to know on #lymphoma #leukemia #myeloma #CART from #ASH25 #ASH2025 and beyond over 3 nights from @Perlmutter_CC @nyulangone experts in partnership with @BloodCancerUtd

[gilberto lopes @GlopesMd]

Top lung cancer developments in 2025?

My take:
2025 wasn’t about a single disruptive moment. It was about consolidation, maturation, and a few long-awaited signals finally turning solid.

1) MARIPOSA delivers OS
Amivantamab + lazertinib demonstrates an overall survival benefit over osimertinib in first-line EGFR-mutant NSCLC. Toxicity, logistics, and sequencing still matter—but this is now a real OS-based conversation, not just a PFS debate.

2) FLAURA2 confirms upfront intensification can matter
Osimertinib + chemotherapy shows improved OS vs osimertinib alone. Reinforces that combination strategies can deepen benefit, at the cost of complexity and tolerability. “Best first-line EGFR strategy” is now legitimately plural.

3) HER2 finally matters clinically
Accelerated approvals for zongertinib and sevabertinib in HER2-mutant NSCLC. Oral TKIs, meaningful response rates, and a credible path beyond antibody-drug conjugates alone.

4) EGFR exon 20 keeps inching forward
Sunvozertinib approved post-platinum. Incremental progress, but still meaningful in a historically difficult molecular subset.

5) c-MET ADC enters routine practice
Telisotuzumab vedotin approved for MET-high NSCLC. Expression-based biomarkers and ADCs are now firmly embedded in lung cancer decision-making.

6) A genuine advance in SCLC
Tarlatamab converts to full approval in platinum-refractory ES-SCLC with a survival benefit. Rare, and important.

7) Companion diagnostics become unavoidable
HER2 TKD, EGFR exon 20, MET expression—therapy is increasingly inseparable from the assay used to define eligibility. Testing strategy is now a core clinical decision.

8) Combination immunotherapy reality check
ATR inhibition + durvalumab misses OS (LATIFY). A reminder that biological plausibility still has to survive Phase 3.

9) AI moves from novelty to infrastructure
Improved CT nodule detection, risk stratification, and workflow support. Still assistive, not autonomous—but no longer theoretical.

10) Direction of travel is clear
More rare targets, more ADCs, OS gains in EGFR-mutant disease, slow but meaningful progress in SCLC—and increasing pressure on systems to deliver precision care at scale.

Bottom line: 2025 didn’t reinvent lung cancer. It made several long-promised ideas finally defensible at the OS level. That’s quieter progress—but it’s the kind that lasts.

#LCSM @SylvesterCancer @IASLC @myESMO @lungoncdoc @Latinamd @COlazagasti @Jani_Chinmay @NarjustFlorezMD @DrJNaidoo @StephenVLiu @EddieSantosMD @RManochakian @LuisRaezMD @uicc

[Toni Choueiri, MD @DrChoueiri]

JUST IN: ⁦@US_FDA⁩ approves Enhertu in combination with Pertuzumab in Metastatic HER2+ Breast Cancer
Based on DESTINY-Breast09 trial ⁦@OncoAlert⁩ ⁦@DFCI_BreastOnc⁩ https://t.co/FPsLyExVYz

[ASCO TECAG @ASCOTECAG]

💫Missed @ASCOTECAG #Trainee & Early Career #Oncologist Lounge sessions #ASCO25?
We turned key panels into editorials so everyone can easily access expert professional development insights!
🔶Series overview https://t.co/vpSdbN2d0j
by @NazliDizman

@ASCO #MedEd #ASCO26 @ASCOPres

[Raul Cordoba, MD, PhD #EHA2026 @DrRaulCordoba]

Kudos to @Othman_Al_Sawaf for his outstanding presentation at the #ASH25 Plenary Session presenting the CLL17 trial: FDT (VO, VI) showed non-inferiority PFS compared with continuous BTKi ibrutinib #hematology #CLL #lymsm